Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 9/20 | 0.51 |
| ▸ | BRAF | P15056 | 7/20 | 0.47 |
| ▸ | RAF1 | P04049 | 10/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.44 |
| ▸ | GCK | P35557 | 1/20 | 0.41 |
| ▸ | PLK4 | O00444 | 2/20 | 0.41 |
| ▸ | AURKA | O14965 | 2/20 | 0.41 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.41 |
| ▸ | ABL1 | P00519 | 2/20 | 0.41 |
| ▸ | LCK | P06239 | 2/20 | 0.41 |
| ▸ | FYN | P06241 | 2/20 | 0.41 |
| ▸ | LYN | P07948 | 2/20 | 0.41 |
| ▸ | RET | P07949 | 2/20 | 0.41 |
| ▸ | SRC | P12931 | 2/20 | 0.41 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.41 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.41 |
| ▸ | AXL | P30530 | 2/20 | 0.41 |
| ▸ | FRK | P42685 | 2/20 | 0.41 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL620695 | 0.85 | RAF1 (0.53) | KDRBRAFRAF1EPHX2MEN1 | |
| SCHEMBL6386070 | 0.84 | KDR (0.47) | KDRBRAFRAF1EPHX2GCK | |
| SCHEMBL177735 | 0.83 | KDR (0.67) | KDRBRAFRAF1EPHX2PLK4 | |
| SCHEMBL16651380 | 0.83 | KDR (0.67) | KDRBRAFRAF1EPHX2PLK4 | |
| SCHEMBL2889234 | 0.80 | GCK (0.52) | KDRBRAFRAF1EPHX2GCK | |
| SCHEMBL1642878 | 0.79 | KDR (0.48) | KDRBRAFRAF1EPHX2PLK4 | |
| SCHEMBL6383415 | 0.78 | KDR (0.47) | KDRBRAFRAF1EPHX2PLK4 | |
| SCHEMBL8213283 | 0.77 | KDR (0.44) | KDRBRAFRAF1EPHX2GCK | |
| SCHEMBL14480928 | 0.77 | KDR (0.56) | KDRBRAFRAF1EPHX2PLK4 | |
| SCHEMBL4334161 | 0.77 | ALDH1A1 (0.47) | KDRBRAFRAF1EPHX2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1973897-B1 | Substituted pyrimidine derivatives useful in the treatment of cancer and other disorders | BAYER IP GMBH (DE) | 2014-05-21 | — | — | EP | disclosed |
| US-8580798-B2 | Substituted pyrimidine derivatives useful in the treatment of cancer and other disorders | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-11-12 | — | — | US | disclosed |
| US-20100081812-A1 | SUBSTITUTED PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISORDERS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2010-04-01 | — | — | US | disclosed |
| EP-1973897-A2 | SUBSTITUTED PYRYMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISORDERS | Bayer HealthCare AG (DE) | 2008-10-01 | — | — | EP | disclosed |
| WO-2007075650-A2 | SUBSTITUTED PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISORDERS | BAYER HEALTHCARE AG (DE) | 2007-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081812-A1 | SUBSTITUTED PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISORDERS | TYMP, DPYD, TYMS | KDR 70/4885BRAF 322/4885RAF1 1469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.